Coherus to Acquire Surface Oncology
16 juin 2023 07h01 HE
|
Coherus BioSciences, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
05 juin 2023 17h30 HE
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
01 juin 2023 08h33 HE
|
Coherus BioSciences, Inc.
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
01 juin 2023 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023*...
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
22 mai 2023 08h30 HE
|
Coherus BioSciences, Inc.
– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need...
Coherus Prices Public Offering of Common Stock
16 mai 2023 06h50 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its...
Coherus Announces Proposed Public Offering of Common Stock
15 mai 2023 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of...
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
08 mai 2023 16h05 HE
|
Coherus BioSciences, Inc.
– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of...
Coherus BioSciences to Present at Upcoming Investor Conferences in May
04 mai 2023 16h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
01 mai 2023 16h07 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market...